NCT01120561View on ClinicalTrials.gov

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

May 31, 2010

Conditions
Metastatic Breast Cancer
Interventions
DRUG

trastuzumab-MCC-DM1

Intravenous repeating dose

Trial Locations (15)

21231

Investigational Site, Baltimore

22031

Investigational Site, Fairfax

28203

Investigational Site, Charlotte

29403

Investigational Site, Charleston

33324

Investigational Site, Plantation

47905

Investigational Site, Lafayette

48201

Investigational Site, Detroit

52403

Investigational Site, Cedar Rapids

63011

Investigational Site, Clarkson Valley

80220

Investigational Site, Denver

87401

Investigational Site, Farmington

92346

Investigational Site, Highland

95204

Investigational Site, Stockton

98109

Investigational Site, Seattle

04074

Investigational Site, Scarborough

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY